Is Tesamorelin FDA-Approved?

Is tesamorelin FDA-approved? Yes, but the approval applies to one specific prescription medication, for one clearly defined medical use.

Tesamorelin is FDA-approved for reducing excess abdominal fat in adults with HIV who have lipodystrophy. It is not FDA-approved for general weight loss, bodybuilding, anti-aging treatment, athletic performance, or routine body-composition management.

Understanding this distinction is important because FDA approval does not automatically apply to every product that carries the name tesamorelin.

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It contains the 44-amino-acid sequence found in human growth hormone-releasing factor, with a modification designed to increase its stability. GHRH signals the pituitary gland to produce and release growth hormone; tesamorelin acts on this pathway, increasing growth hormone secretion and subsequently raising insulin-like growth factor 1 (IGF-1).

Source: FDA prescribing information for EGRIFTA WR.

What Is Tesamorelin FDA-Approved For?

The FDA-approved indication is the reduction of excess abdominal fat in adults with HIV who have lipodystrophy. The approved label also makes several limitations clear:

• Tesamorelin is not indicated for weight-loss management.
• Its long-term cardiovascular safety has not been established.
• Its safety and effectiveness have not been established in children.

Source: FDA prescribing information for EGRIFTA WR.

Does FDA Approval Cover Other Uses?

No. Uses such as general abdominal-fat reduction, obesity treatment, anti-aging care, muscle development, athletic performance, or fatty liver treatment are not included in the FDA-approved indication. There is an important difference between an FDA-approved prescription medication, a compounded product, and a research-labeled product — these categories should not be treated as interchangeable.

Source: FDA explanation of unapproved uses of approved drugs.

The EGRIFTA Family

Tesamorelin is the active ingredient in the EGRIFTA family of prescription products. The FDA first approved EGRIFTA in 2010, and approved EGRIFTA WR in March 2025 as a new formulation and multidose presentation that reduces how frequently a vial must be reconstituted, without changing the approved medical indication.

Source: FDA approval letter for EGRIFTA WR.

Are Compounded or Research-Use Products FDA-Approved?

No. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before marketing. A "research use only" label does not make a product FDA-approved for use in people. The presence of the word tesamorelin on a vial does not establish that it is equivalent to an FDA-approved prescription product.

Source: FDA questions and answers about drug compounding; FDA warning letters regarding unapproved peptide products.